Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients

BACKGROUND: ESR1 mutation in circulating cell-free DNA (cfDNA) is emerging as a noninvasive biomarker of acquired resistance to endocrine therapy, but there is a paucity of data comparing the status of ESR1 gene in cfDNA with that in its corresponding tumor tissue. The objective of this study is to...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeshita, Takashi, Yamamoto, Yutaka, Yamamoto-Ibusuki, Mutsuko, Tomiguchi, Mai, Sueta, Aiko, Murakami, Keiichi, Omoto, Yoko, Iwase, Hirotaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2017
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538967/
https://www.ncbi.nlm.nih.gov/pubmed/28778025
http://dx.doi.org/10.1016/j.tranon.2017.07.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538967/
https://www.ncbi.nlm.nih.gov/pubmed/28778025
http://dx.doi.org/10.1016/j.tranon.2017.07.004

Ejemplares similares